Daily Market Reports | 10:30 AM
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
3DP ACW AEL AMP ANZ AOV ARF ASX AWJ BC8 BRG BVS CBA CIP CLW CSL EOS GEM HDN IAG NST ORA ORG PLS PME TPW
PLS PLS GROUP LIMITED
New Battery Elements - Overnight Price: $4.31
Canaccord Genuity rates ((PLS)) as Buy (1) -
PLS Group has announced a new two-year binding offtake agreement with Chinese battery manufacturer Canmax Technologies for the supply of spodumene concentrate.
PLS has noted it is capable of fulfilling the offtake with Pilgan Plant concentrate given spare capacity following reduced concentrate consumption at its POSCO JV.
Canaccord Genuity also notes the company has been preparing its Ngungaju Plant for a restart.
Buy retained, target $5.30.
This report was published on February 16, 2026.
Target price is $5.30 Current Price is $4.31 Difference: $0.99
If PLS meets the Canaccord Genuity target it will return approximately 23% (excluding dividends, fees and charges).
Current consensus price target is $4.85, suggesting upside of 12.5%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 13.2, implying annual growth of N/A.
Current consensus DPS estimate is 0.8, implying a prospective dividend yield of 0.2%.
Current consensus EPS estimate suggests the PER is 32.7.
Forecast for FY27:
Current consensus EPS estimate is 28.4, implying annual growth of 115.2%.
Current consensus DPS estimate is 4.6, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 15.2.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PME PRO MEDICUS LIMITED
Medical Equipment & Devices - Overnight Price: $116.97
Moelis rates ((PME)) as Hold (3) -
Pro Medicus’ 1H26 result missed expectations held by Moelis, though fundamentals remain intact, according to the broker.
Revenue of $124.8m rose by 28%, with NPAT rising 29%, but both were below consensus on contract timing, explain the analysts. It's noted the earnings (EBIT) margin improved to 73%, up from 72% in H1 FY25.
The broker trims its FY26-28 EPS forecasts by between -2-8% on ramp-up timing and FX, partly offset by repricing. It believes AI risk is limited given regulation, proprietary technology and strong implementation capability.
The analysts expect around 30% annual growth in revenue, supported by a solid pipeline and low US market share.
Moelis retains a Hold rating. The target is lowered to $141.04 from $325.82.
This report was published on February 13, 2026.
Target price is $141.04 Current Price is $116.97 Difference: $24.07
If PME meets the Moelis target it will return approximately 21% (excluding dividends, fees and charges).
Current consensus price target is $273.17, suggesting upside of 133.5%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 67.00 cents and EPS of 139.80 cents.
At the last closing share price the estimated dividend yield is 0.57%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 83.67.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 185.4, implying annual growth of 68.1%.
Current consensus DPS estimate is 67.8, implying a prospective dividend yield of 0.6%.
Current consensus EPS estimate suggests the PER is 63.1.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 96.00 cents and EPS of 189.50 cents.
At the last closing share price the estimated dividend yield is 0.82%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 61.73.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 187.1, implying annual growth of 0.9%.
Current consensus DPS estimate is 89.8, implying a prospective dividend yield of 0.8%.
Current consensus EPS estimate suggests the PER is 62.5.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TPW TEMPLE & WEBSTER GROUP LIMITED
Furniture & Renovation - Overnight Price: $7.64
Petra Capital rates ((TPW)) as Buy (1) -
Petra Capital assesses Temple & Webster's weak point in the first half results was the cost to the margin from the focus on growing market share to take advantage of the shift to online, but considers this a cyclical factor rather than a structural issue for the business.
Some of the positives that have been overlooked in the result include leverage on fixed costs and marketing, intact customer metrics and strongly performing growth areas. Supplier support is also intact.
The broker reduces FY26-28 estimates for EPS by -15-19% and lowers the target to $13.00 from $20.15. Buy rating maintained.
This report was published on February 13, 2026.
Target price is $13.00 Current Price is $7.64 Difference: $5.36
If TPW meets the Petra Capital target it will return approximately 70% (excluding dividends, fees and charges).
Current consensus price target is $15.88, suggesting upside of 107.8%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 10.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 75.64.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 9.9, implying annual growth of 4.0%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 77.2.
Forecast for FY27:
Petra Capital forecasts a full year FY27 dividend of 0.00 cents and EPS of 16.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 47.45.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 18.2, implying annual growth of 83.8%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 42.0.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.